Charles-Lemoyne Hospital urologist Dr Lorne Aaron noted Zytiga provides men and health care professionals with a proven treatment option after failure of androgen deprivation therapy, helping delay the progression of metastatic prostate cancer and improving overall quality of life.
"It also gives urologists like myself, the opportunity to ensure patients will benefit from our expertise for longer and maintain continuity of care," says Dr. Lorne Aaron* Urologist, Charles-Lemoyne Hospital. "I applaud the decision to add ZYTIGA® to the Québec public drug formulary for treatment earlier in advanced disease."
In July 2011, Zytiga was approved by Health Canada for the treatment of men with mCRPC who had received prior chemotherapy containing docetaxel after failure of ADT. Health Canada approved a second indication for Zytiga in May 2013 for the treatment of men with mCRPC who are asymptomatic or mildly symptomatic after failure of ADT.
Quebec joins British Columbia as the second province to add Zytiga to its public formulary for men with mCRPC who are asymptomatic or mildly symptomatic after failure of ADT.